Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Lidan Yi,Qiao Liu,Chongqing Tan,Xiaomin Wan,Xia Luo,Yinbo Li,Haiying Li,Xiaohui Zeng
DOI: https://doi.org/10.2147/rmhp.s475048
2024-11-23
Risk Management and Healthcare Policy
Abstract:Lidan Yi, 1, &ast Qiao Liu, 1, &ast Chongqing Tan, 1 Xiaomin Wan, 1 Xia Luo, 1 Yinbo Li, 2 Haiying Li, 3 Xiaohui Zeng 3 1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China; 2 Hunan Center for Drug Evaluation and Adverse Reaction Monitoring, Hunan Provincial Food and Drug Administration, Changsha, People's Republic of China; 3 Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaohui Zeng; Haiying Li, Email ; Objective: To assess the cost-effectiveness of adding daratumumab to carfilzomib and dexamethasone (KdD) in patients with relapsed or refractory multiple myeloma (RRMM). Materials and Methods: A Markov model was established to estimate health and economic outcomes of carfilzomib and dexamethasone (Kd) with or without daratumumab for RRMM patients over a lifetime horizon. The patients and intervention of the two arms were modeled according to the CANDOR trial. Costs were collected from the Chinese health system perspective. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to evaluate the robustness of our conclusions. Results: Compared with the Kd arm, KdD achieved an additional 0.537 quality-adjusted life-years (QALYs) at an incremental cost of &dollar138,084, resulting in an incremental cost-utility ratios (ICURs) of &dollar257,319 per QALY. Uncertainty analyses revealed that the model is robust to all the input parameters. Conclusion: From the Chinese healthcare system perspective, adding daratumumab to the Kd regimen for patients with RRMM appears to lack cost-effectiveness. Exploring alternative avenues such as negotiating for a more favorable price or introducing a financial assistance program dedicated to daratumumab and/or carfilzomib could prove to be an effective strategy in enhancing accessibility of this combination. Keywords: cost-effectiveness, daratumumab, multiple myeloma, Markov model, China Multiple myeloma (MM) ranks as the second most prevalent hematological malignancy on a global scale. 1 The approval of innovative therapeutics, such as proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies, has led to improved survival rates among MM patients. 2 Nonetheless, a notable portion of patients experience relapse or develop treatment resistance. Carfilzomib, a second-generation proteasome inhibitor (PI), has garnered approval for treating relapsed/refractory multiple myeloma (RRMM). Carfilzomib-containing regimens are prominently featured in treatment guidelines for patients with previously treated myeloma. 3 Daratumumab, a first-in-class IgG1K monoclonal antibody against CD38, was approved by the US Food and Drug Administration (FDA) in 2015. In 2019, daratumumab became the first monoclonal antibody approved for the treatment of multiple myeloma in China. In the CANDOR trial, the addition of daratumumab to carfilzomib and dexamethasone (KdD) showcased a significant extension in progression-free survival (PFS) and a promising trend towards overall survival (OS) benefit when compared to carfilzomib + dexamethasone (Kd) among RRMM patients. 3,4 The median PFS was 28.4 months (95% confidence interval [CI], 22.7–36.2) in the KdD group and 15.2 months (95% CI, 11.1–19.9) in the Kd group, with a hazard ratio (HR) of 0.64 (95% CI, 0.49–0.83). The median OS was 50.8 months (95% CI, 44.7 to not estimable [NE]) in the KdD group and 43.6 months (95% CI, 35.3 to NE), with an HR of 0.78 (95% CI, 0.60–1.03). Compared with the kd regimen, the KdD regimen did not significantly increase the occurrence of adverse reactions. The results of the CANDOR study reinforce the notion that KdD represents a standard of care for RRMM. As of our current knowledge, there is no available publication on the economic evaluation of KdD treatment for patients with RRMM. Nonetheless, studies have evaluated the economic outcomes of daratumumab for patients with RRMM. From a US perspective, our previous research and another study have found that adding daratumumab to either a regimen of Vd (bortezomib and dexamethasone) or Rd (lenalidomide and dexamethasone) did not demonstrate cost-effectiveness. 5,6 Carlson et al conducted a study indicating that daratumumab-based triplet therapies were cost-effective from the US payer perspective. 7 A manufacturer-sponsored analysis compared the cost-effectiveness of pomalidomide, carfilzomib, and dara -Abstract Truncated-
health care sciences & services,health policy & services